Clinical Trials Logo

Advanced Malignant Solid Tumor clinical trials

View clinical trials related to Advanced Malignant Solid Tumor.

Filter by:

NCT ID: NCT04165590 Recruiting - Clinical trials for Advanced Malignant Solid Tumor

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

Start date: October 24, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe and effective course of the Plasmodium immunotherapy for the advanced malignant solid tumors. 3) To explore the possible indications of Plasmodium immunotherapy for advanced malignant solid tumors. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.

NCT ID: NCT03662815 Active, not recruiting - Clinical trials for Advanced Malignant Solid Tumor

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor

Start date: February 7, 2018
Phase: Phase 1
Study type: Interventional

This research study is evaluating a new type of cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced malignant tumor. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced malignant cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients. It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.

NCT ID: NCT03171220 Recruiting - Clinical trials for Advanced Malignant Solid Tumor

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

NRT-01
Start date: June 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor(SHR-1210)in the treatment of Chinese patients with advanced refractory solid tumors.